Daily Intelligence Brief
Daily Docket: Social Media Adds 46; JPML Hears AirTag Bid Sept. 24
We tracked 108 new filings, up from 71. The Social Media Adolescent Addiction Personal Injury Products Liability Litigation (3047) added 46 — about 7% of its 630 trailing-30-day total — with Frantz Law Group APLC filing 29. School-district complaints accounted for 27 of the 46. The Aqueous Film-Forming Foams Personal Injury Products Liability Litigation (2873) added 21, three through Krentsel & Guzman LLP. The Uber Passenger Sexual Assault Litigation (3084) added 7 — Phillips & Associates Law Firm PC 4 and Chaffin Luhana LLP 3. See the full filing feed and firm-level breakdowns here.
EU Kids Act Proposal Puts Platform Design at Center Stage
The European Commission on Sept. 17 proposed the EU Kids Act, placing age-gating and safer-default design at the center of its response to youth social-media use. The proposal would bar children under 13 from social media and limit 13- and 14-year-olds to parent-supervised accounts with restricted features, while requiring stronger protections for older minors. It is not yet binding law and must clear the European Parliament and member states, but it gives Social Media Adolescent Addiction Personal Injury Products Liability Litigation (3047) plaintiffs a current regulatory benchmark for arguments that age verification and product restraints are technically and operationally feasible. The measure also sharpens the evidence fight over whether platform defendants could have deployed youth-safety controls before the alleged injuries at issue.
Paragard Bellwether Receives October Evidentiary Deadline
A Sept. 16 scheduling order gave the second bellwether in Paragard IUD Products Liability Litigation (2974) a defined pretrial track, setting motions in limine for Oct. 22, 2026. The order moves the Robere case beyond a general trial target and forces the parties to identify the evidentiary disputes that will determine what a jury may hear. Those rulings will carry added weight because a bellwether record can shape settlement leverage and the parties’ approach to later cases even without resolving the merits of the broader proceeding. The near-term deadline now concentrates attention on expert proof, product evidence and case-specific defenses before the next trial phase begins.
Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.